Drilldown: Medicines - Pharmacopedia

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Dissociative

or NDRI

or Stimulant

Use the filters below to narrow your results.

None (59) · Benzedrex (1) · DXM (1) · DXO (1) · Focalin, Focalin XR (1) · Ritalin, Ritalin LA, Concerta, Metadate CD, Daytrana, Quillivant XR (1) · Spravato (1)

Monoamine releasing agent (8) · Dopamine/norepinephrine reuptake inhibitor (5) · NMDA antagonist (3) · Cathinone analogue; monoamine reuptake inhibitor (2) · Dopamine and norepinephrine reuptake inhibitor (2) · NMDA antagonist; sigma receptor agonist (2) · Norepinephrine–dopamine reuptake inhibitor (2)

Other values:

None (62) · ADHD, narcolepsy (1) · Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020). (1) · '"`UNIQ--vote-00000150-QINU`"', '"`UNIQ--vote-00000151-QINU`"' (1)

None (64) · Induction (TRD): 56 mg intranasal twice weekly × 4 weeks. Maintenance: 56-84 mg once weekly × 4 weeks, then 56-84 mg every 1-2 weeks. For acute suicidality: 84 mg twice weekly × 4 weeks. Administered under medical supervision in REMS-certified site. (1)

None (64) · 28 mg/device (each dose uses 2 devices) (1)

None (64) · 84 mg per session (1)

None (62) · Intranasal (under direct medical supervision) (1) · Oral (2) · transdermal (1)

None (62) · 20–60 min (oral) (1) · 30–60 min (1) · Within hours of first administration (1)

None (62) · Acute effect ~24 hours; cumulative effect builds with repeated dosing (1) · IR 3–5 h; LA/SR 6–8 h; Concerta 10–12 h; Daytrana ~9 h wear time (1) · IR 4–6 h; XR 8–12 h (1)

None (62) · 2.2 h (IR parent); ~3 h (XR parent) (1) · 2–3 h (parent compound) (1) · ~7-12 hours (1)

None (62) · ~22–25% (1) · ~30% (high first-pass) (1) · ~48% intranasal (1)

None (62) · Avoid; may cause fetal harm (1) · Category C (1) · Pregnancy categories were retired by FDA in 2015. Limited reproductive data with small observational signal for cardiac malformations; risk-benefit decision, with many patients deferring ADHD treatment during pregnancy. See pregnancy_details for the full discussion. (1)

None (62) · Rx, Schedule III (US). REMS program required. (1) · Schedule II (2)

Showing below up to 65 results in range #1 to #65.

2

3

4

A

B

Bromantane

C

Caffeine

D

E

H

Hexedrone

I

M

N

O

O-PCE

P

R

RTI-111

S

T

X

Xenon

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"